Concepedia

Publication | Open Access

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

DOIFull Paper Access

49

Citations

7

References

2023

Year

Andrew H. Ko, Kyu‐pyo Kim, Jens T. Siveke, Charles D. Lopez, Jill Lacy, Eileen M. O’Reilly, Teresa Macarulla, Gulam A. Manji, Jaffer A. Ajani, María Maqueda,
The Oncologist

Abstract

Atezolizumab plus PEGPH20 showed limited clinical activity in patients with PDAC and none in patients with GC. The safety of atezolizumab plus PEGPH20 was consistent with each agent's known safety profile. (ClinicalTrials.gov Identifier: NCT03193190 and NCT03281369).

References

YearCitations

Page 1